Our partner is a global privately held biopharmaceutical company focused on developing and delivering therapeutics to patients with devastating disease and unmet medical needs. The company has an experienced management team, significant funding, and a clear vision of building a global, generational company.

The senior leader was initially responsible for supporting our partner’s efforts to acquire/in-license additional therapeutic assets by helping to identify, evaluate and provide deep scientific due diligence of potential therapeutic targets for diseases. They were also responsible for designing and evaluating in vitro, ex vivo and/or in vivo studies in support of early-stage discovery and development of acquired assets, including the company’s existing therapeutic delivery platform technology.